IL-10抗肝纤维化的实验研究及临床现状
肝纤维化;白介素-10,王小众,张莉娟,王小众,通讯作者:,Statusofexperimentalandclinicalresearchintotheanti-fibroticeffectsofinterleukin-10,Xiao-Zhon
 |
| 第1页 |
参见附件(803KB，4页)。
王小众, 张莉娟, 福建医科大学附属协和医院消化内科 福建省福州市 350001
王小众, 北京大学医学博士, 纽约大学访问医师, 主任医师, 教授, 博士生导师. 国务院特殊津贴专家, 福建省百千万人才, 主要从事肝纤维化实验与临床和乙型肝炎病毒分子病毒学研究.福建省科技计划开发项目, No. 2005D094
通讯作者: 王小众, 350001, 福建省福州市, 福建医科大学协和医院消化内科. drwangxz@pub6.fz.fj.cn
电话: 0591-3357896-8482
收稿日期: 2007-05-18 修回日期: 2007-08-02
Status of experimental and clinical research into the anti-fibrotic effects of interleukin-10
Xiao-Zhong Wang, Li-Juan Zhang
Xiao-Zhong Wang, Li-Juan Zhang,Department of Gastroenterology, Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian Province, China
Supported by:Science and Technology Program of Fujian Province, No. 2005D094
Correspondence to:Xiao-Zhong Wang, Department of Gastroenterology, Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian Province, China. drwangxz @pub6.fz.fj.cn
Received:2007-05-18 Revised:2007-08-02
Abstract
Although liver fibrosis represents a process of healing and scarring in response to chronic liver injury, there is a lack of effective therapy that targets liver fibrosis. Interleukin-10 (IL-10) is a cytokine that down-regulates pro-inflammatory responses. In vitro and animal experiments have suggested that IL-10 plays an important role in hepatic fibrogenesis. Recombinant human IL-10 has been produced and is undergoing clinical trials. IL-10 therapy may be clinically effective against liver fibrosis.
Key Words: Liver fibrosis; Interleukin-10
Wang XZ, Zhang LJ. Status of experimental and clinical research into the anti-fibrotic effects of interleukin-10. Shijie Huaren Xiaohua Zazhi 2007; 15(23): 2469-2472
摘要
肝纤维化是慢性肝损伤时的修复和疤痕形成过程, 目前尚缺乏有效的治疗方法. 白细胞介素-10(IL-10)为一种下调炎症反应的细胞因子, 体内外试验证实其在肝纤维化过程中有重要作用. 重组人IL-10已在临床试用. IL-10可能是治疗肝纤维化的一种有效方法, 具有潜在的临床应用价值.
关键词: 肝纤维化; 白介素-10
王小众, 张莉娟. IL-10抗肝纤维化的实验研究及临床现状. 世界华人消化杂志 2007;15(23):2469-2472 ......
您现在查看是摘要介绍页，详见PDF附件(803KB，4页)。